OTCPK:CTHZ

Stock Analysis Report

Cancer Treatment Holdings

Executive Summary

Cancer Treatment Holdings, Inc., through its subsidiaries, engages in providing IT-enabled services; the exploitation of an invention related to the on-site production of chlorine gas and related compounds; and providing radiation therapy, diagnostic imaging, and other medical related services.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Cancer Treatment Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CTHZ's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

CTHZ

2.6%

US IT

1.2%

US Market


1 Year Return

n/a

CTHZ

41.9%

US IT

24.2%

US Market

Return vs Industry: Insufficient data to determine how CTHZ performed against the US IT industry.

Return vs Market: Insufficient data to determine how CTHZ performed against the US Market.


Shareholder returns

CTHZIndustryMarket
7 Day0%2.6%1.2%
30 Day-20.0%6.3%3.5%
90 Day53.8%17.4%11.7%
1 Yearn/a43.3%41.9%26.9%24.2%
3 Yearn/a109.6%100.7%53.0%43.2%
5 Yearn/a156.2%133.4%75.3%56.0%

Price Volatility Vs. Market

How volatile is Cancer Treatment Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Cancer Treatment Holdings undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Cancer Treatment Holdings is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Cancer Treatment Holdings has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of CTHZ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Cancer Treatment Holdings regulatory filings here.
  • Explore potentially undervalued companies in the Software industry.

Future Growth

How is Cancer Treatment Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

17.2%

Forecasted Software industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Cancer Treatment Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Take a look at our analysis of CTHZ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Cancer Treatment Holdings's filings and announcements here.
  • Explore growth companies in the Software industry.

Past Performance

How has Cancer Treatment Holdings performed over the past 5 years?

10.7%

Historical Software annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Cancer Treatment Holdings has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Cancer Treatment Holdings's financial position?


In this section we usually analyse Cancer Treatment Holdings's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Cancer Treatment Holdings has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of CTHZ’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Cancer Treatment Holdings's financial data was last updated here.
  • Explore more healthy companies in the Software industry.

Dividend

What is Cancer Treatment Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CTHZ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CTHZ's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CTHZ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CTHZ's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CTHZ's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Cancer Treatment Holdings's salary, the management and board of directors tenure and is there insider trading?

26.5yrs

Average board tenure


CEO

Ullrich Klamm (80yo)

0yrs

Tenure

US$156,600

Compensation

Ullrich Klamm Ph.D. has been a Director of Cancer Treatment Holdings Inc. since 1993, and also serves as Chairman of the Board, Chief Executive Officer, Chief Financial Officer and President. Since 1987, D ...


Board Age and Tenure

26.5yrs

Average Tenure

85yo

Average Age

Experienced Board: CTHZ's board of directors are seasoned and experienced ( 26.5 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Management Team

  • Ullrich Klamm (80yo)

    Chairman of the Board

    • Compensation: US$156.60k
  • Mark Stephenson (59yo)

    Secretary

    • Tenure: 17.4yrs

Board Members

  • John Mull (85yo)

    Director

    • Tenure: 26yrs
  • John Rosenthal (85yo)

    Director

    • Tenure: 27yrs
  • Jack Buechner (79yo)

    Director

    • Tenure: 27yrs
  • Ullrich Klamm (80yo)

    Chairman of the Board

    • Compensation: US$156.60k
  • Salvatore Russo (89yo)

    Director

    • Tenure: 26yrs

Company Information

Cancer Treatment Holdings, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cancer Treatment Holdings, Inc.
  • Ticker: CTHZ
  • Exchange: OTCPK
  • Founded:
  • Industry: Data Processing and Outsourced Services
  • Sector: Software
  • Market Cap: US$133.440k
  • Shares outstanding: 3.34m
  • Website: https://null

Location

  • Cancer Treatment Holdings, Inc.
  • 202 North Curry Street
  • Suite 100
  • Carson City
  • Nevada
  • 89703
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CTHZOTCPK (Pink Sheets LLC)YesCommon StockUSUSDSep 1988

Biography

Cancer Treatment Holdings, Inc., through its subsidiaries, engages in providing IT-enabled services; the exploitation of an invention related to the on-site production of chlorine gas and related compounds; and providing radiation therapy, diagnostic imaging, and other medical related services. The company, through a 50% interest in a joint venture, offers IT-enabled services, including medical transcriptions, billing and collecting, bookkeeping, and claims processing services. The company enables users to manufacture chlorine on-site and when needed through its device. It has a 51% interest in a radiation therapy center located in Logan, West Virginia. In addition, through its wholly owned subsidiary, CTI Management Corp., the company's president provides management services. The company is based in Carson City, Nevada. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/01/20 23:58
End of Day Share Price2020/01/08 00:00
Earnings2003/02/28
Annual Earnings2002/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.